Results 101 to 110 of about 15,823 (164)

Brain and Spinal Leptomeningeal Metastases in Prostate Cancer Detected by PSMA PET and MRI Fusion. [PDF]

Clin Nucl Med
Wang J, Kuker R.
europepmc   +1 more source

Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation

International Journal of Urology, Volume 33, Issue 8, August 2026.
ABSTRACT Background Radium‐223 dichloride (Ra‐223) is an effective treatment for metastatic castration‐resistant prostate cancer (mCRPC) with bone metastases. However, predictive factors associated with treatment efficacy remain unclear. This study evaluated prognostic factors associated with the efficacy of Ra‐223 and investigated outcomes according ...
Kodai Abe, Yoshiyuki Miyazawa, Shun Nakazawa, Mai Onose, Yuta Maeno, Yusuke Tsuji, Azusa Kanayama, Akira Ohtsu, Yuji Fujizuka, Seiji Arai, Masashi Nomura, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Kazuhiro Suzuki   +14 more
wiley   +1 more source

Comparative Analysis of ISM-1 and B7-H3 Expression in Castration-Resistant Prostate Adenocarcinoma: Associations with Tumor Aggressiveness and Resistance Dynamics. [PDF]

Medicina (Kaunas)
Kaya Ş, Öztürk A, Yüceer RO, Öztürk NB.   +3 more
europepmc   +1 more source

Development of Prostate Cancer Intramuscular Metastasis During 177 Lu-PSMA-617 Treatment. [PDF]

Clin Nucl Med
Xie VK, Jahromi AH.
europepmc   +1 more source

HIF1 inhibition targets tumoral and myeloid cells, and is a promising therapy for metastatic castration-resistant prostate cancer. [PDF]

Cell Death Dis
Yanushko D, Pichot A, Vincent A, Keime C, Laverny G, Metzger D.   +5 more
europepmc   +1 more source

Testosterone Replacement in Prostate Carcinoma: A Systematic Review of an Emerging Paradigm and Therapeutic Potential. [PDF]

Cureus
Robinson J, Banerjee I, Banerjee I.
europepmc   +1 more source

Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). [PDF]

J Immunother Cancer
Kyriakopoulos CE, Pachynski RK, Eickhoff JC, Tonelli TP, Jeon D, McNeel DG.   +5 more
europepmc   +1 more source

Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs). [PDF]

Gene
Pederzoli F, Pakula H, Rodrigues S, Garner R, Nuzzo PV, Bleve S, Rickman DS, Fanelli GN, Loda M.   +8 more
europepmc   +1 more source

Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer. [PDF]

Pathol Int
Hodgson K, Blencoe L, Smith E, Sasikumar A, Peng Z, Orozco-Moreno M, Beatson R, Videira PA, Munkley J.   +8 more
europepmc   +1 more source

Neuroendocrine Transformation Without PSA Elevation in High-Risk Metastatic Castration-Sensitive Prostate Cancer Under Androgen Receptor Signaling Inhibition: A Case Report. [PDF]

IJU Case Rep
Nakagami Y, Ohnuma S, Tamaoka M, Inoue T, Yamagishi M, Oshinomi K, Nagata M, Oohira Y, Yamochi T, Fukagai T.   +9 more
europepmc   +1 more source